Captrust Financial Advisors Lowers Holdings in Harrow, Inc. (NASDAQ:HROW)

Captrust Financial Advisors reduced its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 14.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 72,920 shares of the company's stock after selling 12,219 shares during the quarter. Captrust Financial Advisors owned 0.20% of Harrow worth $2,446,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Woodmont Investment Counsel LLC lifted its position in shares of Harrow by 0.5% during the 4th quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company's stock valued at $2,731,000 after buying an additional 445 shares in the last quarter. Swiss National Bank lifted its holdings in Harrow by 1.0% in the 4th quarter. Swiss National Bank now owns 59,300 shares of the company's stock worth $1,990,000 after purchasing an additional 600 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Harrow by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock worth $253,000 after purchasing an additional 727 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Harrow by 5.7% in the 4th quarter. MetLife Investment Management LLC now owns 18,908 shares of the company's stock worth $634,000 after purchasing an additional 1,026 shares in the last quarter. Finally, HighTower Advisors LLC lifted its holdings in Harrow by 13.8% in the 4th quarter. HighTower Advisors LLC now owns 10,127 shares of the company's stock worth $340,000 after purchasing an additional 1,227 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HROW has been the topic of a number of research reports. HC Wainwright lifted their price objective on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, May 12th. B. Riley reduced their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st.

Harrow Trading Up 10.9%

Shares of NASDAQ HROW traded up $2.79 during trading hours on Friday, hitting $28.41. 633,665 shares of the company traded hands, compared to its average volume of 498,095. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -30.22 and a beta of 0.41. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The company's 50 day moving average price is $25.02 and its 200 day moving average price is $31.91. Harrow, Inc. has a 12 month low of $15.97 and a 12 month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). The business had revenue of $47.83 million during the quarter, compared to the consensus estimate of $57.00 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. On average, equities research analysts anticipate that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.